Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere Technologies has entered into an exclusive development and license agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen Technology.
Subscribe to our email newsletter
The Insulin agreement includes $57.5m in potential product development and sales milestone payments to Emisphere, of which $5m will be payable upon signing, as well as royalties on sales
Emisphere’s drug delivery technology platform, known as the Eligen Technology, uses proprietary, synthetic chemical compounds, known as Emisphere delivery agents, sometimes called carriers.
The technology can be applied to the oral route of administration as well as other delivery pathways such as buccal, rectal, inhalation, intra-vaginal or transdermal
Emisphere claims Eligen Technology makes it possible to deliver a therapeutic molecule without altering its chemical form or biological integrity.
Novo Nordisk Diabetes Research Unit senior vice president Peter Kurtzhals said this is an encouraging agreement on a technology for oral administration of proteins.